{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:33:59Z","timestamp":1780328039755,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1002\/jps.23680","type":"journal-article","created":{"date-parts":[[2013,7,29]],"date-time":"2013-07-29T18:18:54Z","timestamp":1375121934000},"page":"3838-3843","source":"Crossref","is-referenced-by-count":24,"title":["Effect of Venlafaxine and Desvenlafaxine on Drug Efflux Protein Expression and Biodistribution In Vivo"],"prefix":"10.1016","volume":"102","author":[{"given":"Corbin","family":"Bachmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary M.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Beaulieu-Abdelahad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1002\/jps.23680_bb0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood\u2013brain barrier active efflux transporters: ATP-binding cassette gene family","volume":"2","author":"Loscher","year":"2005","journal-title":"NeuroRx"},{"issue":"1","key":"10.1002\/jps.23680_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"10.1002\/jps.23680_bb0020","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s11095-009-9924-0","article-title":"The role of transporters in the pharmacokinetics of orally administered drugs","volume":"26","author":"Shugarts","year":"2009","journal-title":"Pharm Res"},{"issue":"8","key":"10.1002\/jps.23680_bb0025","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1634\/theoncologist.12-8-927","article-title":"Concise review: Clinical relevance of drug\u2013drug and herb\u2013drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein)","volume":"12","author":"Marchetti","year":"2007","journal-title":"Oncologist"},{"issue":"3","key":"10.1002\/jps.23680_bb0030","first-page":"38","article-title":"P-glycoprotein: Why this drug transporter may be clinically important","volume":"11","author":"Levin","year":"2012","journal-title":"Curr Psychiatry"},{"issue":"2","key":"10.1002\/jps.23680_bb0035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin","volume":"104","author":"Greiner","year":"1999","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1002\/jps.23680_bb0040","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/sj.clpt.6100191","article-title":"Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol","volume":"81","author":"Schwarz","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1002\/jps.23680_bb0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hup.820","article-title":"Venlafaxine induces P-glycoprotein in human Caco-2 cells","volume":"22","author":"Ehret","year":"2007","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"10.1002\/jps.23680_bb0050","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/bdd.753","article-title":"Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine","volume":"32","author":"Bachmeier","year":"2011","journal-title":"Biopharm Drug Dispos"},{"issue":"9","key":"10.1002\/jps.23680_bb0055","first-page":"1008","article-title":"Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues","volume":"32","author":"Matheny","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1002\/jps.23680_bb0060","first-page":"2268","article-title":"Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue","volume":"52","author":"Hendricks","year":"1992","journal-title":"Cancer Res"},{"issue":"18","key":"10.1002\/jps.23680_bb0065","first-page":"4559","article-title":"Overexpression of the BCRP\/MXR\/ABCP gene in a topotecan-selected ovarian tumor cell line","volume":"59","author":"Maliepaard","year":"1999","journal-title":"Cancer Res"},{"issue":"12","key":"10.1002\/jps.23680_bb0070","first-page":"1","article-title":"Desvenlafaxine: Frequently asked questions","volume":"16","author":"Cohen","year":"2009","journal-title":"Prim Psychiatry"},{"issue":"9","key":"10.1002\/jps.23680_bb0075","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.euroneuro.2010.04.004","article-title":"Blood\u2013brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein","volume":"20","author":"Karlsson","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"10.1002\/jps.23680_bb0080","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/026988110201600413","article-title":"Venlafaxine: The relationship between dose, plasma concentration and clinical response in depressive patients","volume":"16","author":"Charlier","year":"2002","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1002\/jps.23680_bb0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/JCP.0b013e318192e4c1","article-title":"Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers","volume":"29","author":"Preskorn","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1002\/jps.23680_bb0090","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/11586630-000000000-00000","article-title":"Pharmacokinetics of venlafaxine extended release 75mg and desvenlafaxine 50mg in healthy CYP2D6 extensive and poor metabolizers: A randomized, open-label, two-period, parallel-group, crossover study","volume":"31","author":"Nichols","year":"2011","journal-title":"Clin Drug Investig"},{"issue":"8","key":"10.1002\/jps.23680_bb0095","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0006-3223(03)00074-X","article-title":"Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption","volume":"54","author":"Uhr","year":"2003","journal-title":"Biol Psychiatry"},{"issue":"6","key":"10.1002\/jps.23680_bb0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/1099-1077(200008)15:6<453::AID-HUP228>3.0.CO;2-F","article-title":"Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine","volume":"15","author":"Charlier","year":"2000","journal-title":"Hum Psychopharmacol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491530887X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491530887X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T04:26:12Z","timestamp":1539491172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235491530887X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S002235491530887X"],"URL":"https:\/\/doi.org\/10.1002\/jps.23680","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}